Some patients with myelodysplastic syndromes, like acute myeloid leukemia, benefit from a chemotherapy drug called decitabine that stunts cancer growth. But many others are resistant to decatibine's effects or become resistant ...
Nov 16, 2023
0
3
When Mauricio Ferrato completed his doctorate in computer and information sciences at the University of Delaware a few months ago, he made his mark in more ways than one.
Nov 15, 2023
0
1
A team at Weill Cornell Medicine has mapped the location and spatial features of blood-forming cells within human bone marrow. Their findings confirm hypotheses about the anatomy of this tissue and provide a powerful new ...
Nov 14, 2023
0
0
A new editorial perspective titled "C/EBPβ cooperates with MYB to maintain the oncogenic program of AML cells" has been published in Oncotarget.
Nov 13, 2023
0
0
A novel assay that detects a unique molecular marker in patients with acute myeloid leukemia (AML) may revolutionize the way this disease is detected and treated according to a new report in The Journal of Molecular Diagnostics. ...
Nov 13, 2023
0
0
A new editorial paper was published in Oncotarget, titled "Impact of SHP2 tyrosine phosphorylation on the development of acquired resistance to allosteric SHP2 inhibitors."
Nov 8, 2023
0
0
A new targeted drug, studied by researchers at The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC—James), may offer a new treatment option ...
Nov 6, 2023
0
37
Cancer cells are often a mess of mutations. About 20% to 25% of cancers involve mutations in a complex of molecules called SWI/SNF. Yet drugs designed to block SWI/SNF activity haven't always worked as expected. Researchers ...
Nov 3, 2023
0
42
A discovery by a QIMR Berghofer-led team of international scientists has potentially unlocked an entirely new approach to targeting the blood cancer acute myeloid leukemia, bringing hope to patients who are no longer responding ...
Oct 30, 2023
0
40
Children with Down syndrome have an increased risk of developing acute lymphoblastic leukemia (ALL) and experience higher rates of relapse and treatment toxicity. In recent decades, new therapies have improved outcomes for ...
Oct 30, 2023
0
0
